Browsing Tag
Hong Kong
82 posts
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens
Nexsen has FDA pathway momentum and Asia hospital validation. The harder test is whether ASX: NXN can turn StrepSure into revenue.
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.
Why is Apple supplier Luxshare Precision raising $3.1bn after its Shenzhen stock doubled?
Apple supplier Luxshare Precision Industry is seeking up to $3.1 billion from a Hong Kong H-share offering, financing an aggressive push into automotive electronics, data-centre infrastructure, automation and global manufacturing.
Racura Oncology (ASX:RAC) funds three cancer trials, but can RC220 justify the valuation?
Racura Oncology has funded three RC220 trials, but valuation now depends on clinical proof. Can ASX:RAC turn capital into decisive cancer data?
Restaurant micro-cap RIKU heads to Nasdaq on May 27 with $34.5m Japanese dining bet
RIKU's IPO was withdrawn in March, then refiled larger. A 2.7M-share resale window outside the lock-up may decide how 27 May trades on Nasdaq.
U Power stock faces execution test as UCAR pivots from EV battery swapping to AI energy infrastructure
UCAR’s margin story improved, but losses widened. U Power Limited now needs to prove its EV swapping and AI energy pivot can scale.
Prudential plc Q1 2026 update shows Asia insurance growth is still doing the heavy lifting
Prudential’s Asia growth is intact, but PRU shares slipped. The bigger test is whether margins and buybacks can keep investors patient.
Republic Power Group (RPGL) bets on blockchain infrastructure as RWA tokenization demand accelerates
RPGL wants in on tokenized assets. The real test is whether blockchain access can become scalable institutional revenue.
UCO Bank (NSE: UCOBANK) Q4 FY2026 profit rises 22.66% as loan growth and asset quality strengthen
UCO Bank’s loan growth is accelerating while the stock is still below its highs. Is FY2026 the start of a PSU bank re-rating?